Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jan 21;9(1):e024251.
doi: 10.1136/bmjopen-2018-024251.

Population-based cohort of 500 patients with Gaucher disease in Israel

Dena H Jaffe  1 , Natalie Flaks-Manov  2 , Arriel Benis  2 , Hagit Gabay  2 , Marco DiBonaventura  3 , Hanna Rosenbaum  4 , Alain Joseph  5 , Asaf Bachrach  2 , Maya Leventer-Roberts  2
Affiliations

Population-based cohort of 500 patients with Gaucher disease in Israel

Dena H Jaffe et al. BMJ Open. .

Abstract

Objective: To characterise a population-based cohort of patients with Gaucher disease (GD) in Israel relative to the general population and describe sociodemographic and clinical differences by disease severity (ie, enzyme replacement therapy [ERT] use).

Design: A cross-sectional study was conducted.

Setting: Data from the Clalit Health Services electronic health record (EHR) database were used.

Participants: The study population included all patients in the Clalit EHR database identified as having GD as of 30 June 2014.

Results: A total of 500 patients with GD were identified and assessed. The majority were ≥18 years of age (90.6%), female (54.0%), Jewish (93.6%) and 34.8% had high socioeconomic status, compared with 19.0% in the general Clalit population. Over half of patients with GD with available data (51.0%) were overweight/obese and 63.5% had a Charlson Comorbidity Index ≥1, compared with 46.6% and 30.4%, respectively, in the general Clalit population. The majority of patients with GD had a history of anaemia (69.6%) or thrombocytopaenia (62.0%), 40.4% had a history of bone events and 22.2% had a history of cancer. Overall, 41.2% had received ERT.

Conclusions: Establishing a population-based cohort of patients with GD is essential to understanding disease progression and management. In this study, we highlight the need for physicians to monitor patients with GD regardless of their ERT status.

Keywords: electronic health records; enzyme replacement therapy; ert; gaucher disease.

PubMed Disclaimer

Conflict of interest statement

Competing interests: NF-M, AB, HG, NF-M, AB and ML-R have nothing to declare. DHJ is and MD was employed by Kantar Health, which received fees from Shire for data analysis and reporting of this study. AJ was full-time employee of Shire at the time of the study.

Figures

Figure 1
Figure 1
Prevalence of Gaucher disease in the Clalit population by age group and sex, 2014.
See this image and copyright information in PMC

References

    1. Grabowski GA, Kolodny EH, Weinreb NJ, et al. . Gaucher disease: phenotypic and genetic variation : Scriver C, Beaudet A, Valle D, Slye W. The online metabolic and molecular bases of inherited disease. New York: McGraw-Hill Medical, 2010.
    1. Stirnemann J, Belmatoug N, Camou F, et al. . A Review of Gaucher disease pathophysiology, clinical presentation and treatments. Int J Mol Sci 2017;18:441 10.3390/ijms18020441 - DOI - PMC - PubMed
    1. Zimran A. How I treat Gaucher disease. Blood 2011;118:1463–71. 10.1182/blood-2011-04-308890 - DOI - PubMed
    1. Agency EM. Gaucher disease A strategic collaborative approach from EMA and FDA Gaucher disease A Strategic Collaborative Approach from EMA and FDA Table of contents. London, 2014.
    1. Mehta A. Epidemiology and natural history of Gaucher’s disease. Eur J Intern Med 2006;17:S2–5. 10.1016/j.ejim.2006.07.005 - DOI - PubMed

Publication types

MeSH terms